Provided by Tiger Trade Technology Pte. Ltd.

Aligos Therapeutics, Inc.

6.67
+0.23003.57%
Post-market: 6.670.00000.00%19:30 EDT
Volume:52.33K
Turnover:345.53K
Market Cap:41.65M
PE:-0.91
High:6.80
Open:6.48
Low:6.40
Close:6.44
52wk High:13.69
52wk Low:3.98
Shares:6.24M
Float Shares:3.70M
Volume Ratio:0.71
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.3016
EPS(LYR):-2.4500
ROE:-113.59%
ROA:-49.12%
PB:1.31
PE(LYR):-2.72

Loading ...

Aligos Hepatitis B Trial Completion: What Phase 1 Liver Data Mean for ALGS Investors

TIPRANKS
·
Yesterday

Aligos Says Partner Amoytop Doses First Participant in Phase 1 Trial of HBV Drug ALG-170675 in China

Reuters
·
Aug 13

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of Its Potentially Best-in-Class Antisense Oligonucleotide Alg-170675 by Its Partner Amoytop in China

THOMSON REUTERS
·
Aug 13

Piper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)

TIPRANKS
·
Aug 07

Oculis Q2 Net Loss Narrows Despite Higher Expenses

Reuters
·
Aug 07

Aligos Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate

Benzinga Earnings
·
Aug 06

Aligos Q2 FY26 Net Loss Narrows 91% to $1.5 Million

Reuters
·
Aug 06

Aligos Therapeutics Q2 EPS USD -0.14

THOMSON REUTERS
·
Aug 06

Aligos Therapeutics Q2 Operating Expenses USD 29.668 Million

THOMSON REUTERS
·
Aug 06

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

GlobeNewswire
·
Aug 06

Aligos Therapeutics, Inc. Expected to Post a Loss of $1.07 a Share - Earnings Preview

Reuters
·
Aug 04

Aligos Therapeutics Inc Expected to Post a Loss of $1.07 a Share - Earnings Preview

Reuters
·
Jul 31

Aligos Therapeutics to Report Q2 2026 Financial Results

Reuters
·
Jul 30

Analyst Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target Amid Strengthened HBV Trial Outlook

TIPRANKS
·
Jul 14

Aligos Completes Enrollment in Phase 2 B-supreme Trial for Chronic Hepatitis B Drug Pevifoscorvir Sodium

Reuters
·
Jul 13

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-supreme Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic Hbv Infection

THOMSON REUTERS
·
Jul 13

Aligos Therapeutics - Topline Safety and Efficacy Data Expected in Late Q3 2027

THOMSON REUTERS
·
Jul 13

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

GlobeNewswire
·
Jul 13

Aligos Therapeutics' Shares Rally Following $25M Payment from Xiamen Amoytop Biotech

Dow Jones
·
Jul 07